Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.

Cejalvo, María JLegarda, MarioAbella, EugeniaCabezudo, ElenaEncinas, CristinaGarcía-Feria, AnaGironella, MercedesIñigo, BelénMartín, JesúsRibas, PazRuíz, Mª ÁngelesGonzález, YolandaVicuña, IsabelRamírez, ÁngelFernández, Pascualde la Rubia, Javier2023-02-082023-02-082019-12-02http://hdl.handle.net/10668/14782endaratumumabdialysismultiple myelomarelapseAgedAntibodies, MonoclonalDisease-Free SurvivalFemaleHumansMaleMiddle AgedMultiple MyelomaRecurrenceRenal DialysisRetrospective StudiesSurvival RateSingle-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study.research article31792926open access10.1111/bjh.162861365-2141https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.16286